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Human T cell acute lymphoblastic leukemia 
(T-ALL) arises in thymocyte precursors through 
stepwise alterations in molecular pathways that 
often include the aberrant expression of intact 
master developmental regulatory transcrip-
tion factors (Look, 1997; Ferrando et al., 2002; 
Armstrong and Look, 2005). One such tran-
scription factor is TAL1/SCL, which is required 
for definitive hematopoiesis in early hemato-
poietic stem cells (HSCs), and is expressed by 
immature thymocytes after they migrate to 
the thymus, continuing until they reach the 
double negative 2 (DN2) stage of differentia-
tion, after which its levels are progressively 
down-regulated (Herblot et al., 2000; Lacombe 
et al., 2010; Lécuyer and Hoang, 2004; Porcher 
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The oncogenic transcription factor TAL1/SCL is aberrantly expressed in 60% of cases of 
human T cell acute lymphoblastic leukemia (T-ALL) and initiates T-ALL in mouse models.  
By performing global microRNA (miRNA) expression profiling after depletion of TAL1, 
together with genome-wide analysis of TAL1 occupancy by chromatin immunoprecipitation 
coupled to massively parallel DNA sequencing, we identified the miRNA genes directly 
controlled by TAL1 and its regulatory partners HEB, E2A, LMO1/2, GATA3, and RUNX1.  
The most dynamically regulated miRNA was miR-223, which is bound at its promoter and 
up-regulated by the TAL1 complex. miR-223 expression mirrors TAL1 levels during thymic 
development, with high expression in early thymocytes and marked down-regulation after 
the double-negative-2 stage of maturation. We demonstrate that aberrant miR-223 up-
regulation by TAL1 is important for optimal growth of TAL1-positive T-ALL cells and that 
sustained expression of miR-223 partially rescues T-ALL cells after TAL1 knockdown. 
Overexpression of miR-223 also leads to marked down-regulation of FBXW7 protein  
expression, whereas knockdown of TAL1 leads to up-regulation of FBXW7 protein levels, 
with a marked reduction of its substrates MYC, MYB, NOTCH1, and CYCLIN E. We conclude 
that TAL1-mediated up-regulation of miR-223 promotes the malignant phenotype in T-ALL 
through repression of the FBXW7 tumor suppressor.
© 2013 Mansour et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
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RESULTS
The TAL1 complex regulates a select  
number of miRNAs in T-ALL
We first sought to determine which miRNAs were either 
primary or secondary targets of the TAL1 oncoprotein by as-
sessing changes in miRNA expression after knockdown of 
TAL1 in Jurkat cells, a T-ALL cell line that aberrantly ex-
presses TAL1. By depleting TAL1 using two independent 
short-hairpin RNAs (shRNAs1 and 2; Fig. 1 A), and assessing 
global changes in miRNA expression using a locked nucleic 
acid (LNA)–based profiling platform, we identified signifi-
cant changes in the expression of 22 miRNAs (Fig. 1 B). 9 of 
these were down-regulated on TAL1 knockdown (hence posi-
tively regulated by TAL1), whereas 13 were up-regulated (hence 
negatively regulated by TAL1). Because many of these changes 
were likely to be secondary, we used ChIP-seq analysis of 
TAL1 binding with its binding partners HEB, E2A, GATA3, 
and RUNX1 (Sanda et al., 2012) to address this issue. Of the 
22 regulated miRNAs, five (miR-223, miR-181a*, miR-29c, 
miR-26a and miR-620) were judged to be direct targets of 
the TAL1 complex based on our ChIP-seq data, with evidence 
of TAL1 occupancy within 12 kb of the candidate miRNA 
gene or binding a nearby enhancer (Fig. 1 B, red bars).
miR-223 is directly regulated by the TAL1  
complex in TAL1-positive T-ALL
Of the five miRNAs directly regulated by TAL1, we chose to 
focus on miR-223, because it exhibited the most robust down-
regulation after TAL1 knockdown. After using qRT-PCR to 
confirm the changes we had identified by miRNA expression 
profiling (Fig. 1 C), we asked whether miR-223 was regulated 
by TAL1 in TAL1-positive T-ALL cell lines other than Jurkat 
cells. Knockdown with both TAL1 shRNAs1 and 2 in the 
TAL1-positive T-ALL cell lines RPMI-8402 and CCRF-CEM 
(each harboring an activating SIL-TAL1 deletion) resulted in 
down-regulation of miR-223 as determined by qRT-PCR, 
similar to our results in Jurkat cells (Fig. 1, D and E). We also 
examined the changes in miR-223 expression in an inducible 
TAL1 knockdown model previously established in Jurkat cells 
that expresses a TAL1 shRNA upon addition of doxycycline 
(termed Jurkat S1C1 cells; Palii et al., 2011). In agreement 
with our results from lentiviral knockdown, we found marked 
down-regulation of miR-223 after TAL1 depletion (Fig. 1 F). 
Furthermore, transduction of the TAL1-negative cell line 
KOPT-K1 with TAL1 shRNAs 1 and 2 did not affect miR-223 
expression by qRT-PCR (unpublished data), consistent with 
the interpretation that TAL1 depletion mediates the reduc-
tion in miR-223 in TAL1-positive cell lines. Thus, the ex-
pression of miR-223 is consistently and directly activated by 
TAL1 in T-ALL.
Next, we examined the miR-223 locus in detail in TAL1-
positive T-ALLs, including two cell lines (Jurkat and CCRF-
CEM) and two “primagraft” samples (designated “Prima 2” 
and “Prima 5”), which were derived from primary T-ALL cells 
expanded in immunocompromised mice without prior ex-
posure to in vitro culture. In all four T-ALL samples, a region 
et al., 1996). Activation of TAL1 expression through intra-
chromosomal deletion (SIL-TAL) or chromosomal transloca-
tion occurs in 30% of patients, yet up to 60% of cases of 
T-ALL overexpress TAL1 through unknown mechanisms 
(Ferrando et al., 2002; Aifantis et al., 2008). TAL1-positive 
T-ALL is characterized by an arrest in differentiation at the 
CD4+CD8+ double-positive (DP) stage of thymocyte devel-
opment, when the TAL1 gene is normally silent (Larson et al., 
1996; Ferrando et al., 2002; Aifantis et al., 2008; Tremblay 
et al., 2010). Thus, transcriptional activity of TAL1 is clearly 
aberrant in T-ALL lymphoblasts compared with their normal 
DP counterparts.
The TAL1 gene encodes a class II basic helix–loop–helix 
(bHLH) transcription factor that binds E-box motifs only after 
heterodimerization with one of the class I bHLH E-proteins, 
such as E2A or HEB (Hsu et al., 1991; Hsu et al., 1994). Sev-
eral of the core components of the transcriptional complex 
have now been elucidated and include GATA3, LIM domain 
only 1/2 (LMO1/2), and runt-related transcription factor 1 
(RUNX1; Wadman et al., 1997; Lécuyer et al., 2002; Xu et al., 
2003; Palii et al., 2011). Together, members of the core com-
plex differentially interact with co-activators, such as the his-
tone acetyltransferases p300 and p300/CBP-associated factor 
(PCAF), or with co-repressors such as SIN3A and histone 
deacetylase 1/2 (HDAC1/2; Huang et al., 1999; Huang and 
Brandt, 2000). Accordingly, binding of the TAL1 complex to 
promoter/enhancer regions can exert either a positive or nega-
tive influence on target gene expression.
We recently generated high-resolution maps of the genome-
wide occupancy of the TAL1 complex in human T-ALL, 
which includes E2A, HEB, LMO1/2, GATA3, and RUNX1, 
using chromatin immunoprecipitation coupled to massively 
parallel DNA sequencing (ChIP-seq; Sanda et al., 2012). This 
analysis established that TAL1 acts predominantly as a positive 
regulator of the expression of its direct target genes, forms a 
positive interconnected auto-regulatory loop involving other 
members of the TAL1 complex, and activates several impor-
tant target genes, including the MYB and TRIB2 oncogenes. 
Despite the emerging regulatory roles of miRNAs in normal 
and malignant hematopoiesis (Chen et al., 2004; Calin and 
Croce, 2006; Mavrakis et al., 2011), the underlying transcrip-
tional mechanisms leading to dysregulated miRNA expression 
in cancer and T-ALL in particular remain poorly understood. 
Thus, we investigated whether the TAL1 complex might in-
teract with regulatory sequences of one or more of these 
miRNAs to regulate downstream targets with critical func-
tions in T-ALL.
Here, we report the results of a genome-wide survey of 
TAL1 binding of miRNA genes by ChIP-seq in both T-ALL 
cell lines and primary cells, together with an analysis of changes 
in miRNA gene expression after TAL1 depletion. This strategy 
has allowed us to identify the miR-223 gene as an important 
direct transcriptional target of TAL1 in normal and malignant 
T cells. We show that TAL1 down-regulates the expression 
of the critical tumor suppressor protein FBXW7 through 
miR-223, thus promoting the malignant phenotype in T-ALL.
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the transcriptional co-activator CREB-binding protein (CBP). 
The promoter and body of the miR-223 gene had high levels 
of trimethyl histone H3 on lysine 4 (H3K4me3) and dimethyl 
histone H3 on lysine 79 (H3K79me2) and broad enrichment 
within 4 kb of the miR-223 transcriptional start site was oc-
cupied by TAL1, HEB, E2A, LMO1/2, GATA3 and RUNX1 
(Fig. 2 A), a result validated by ChIP-qPCR (Fig. 2 B). Fur-
thermore, this putative regulatory element was co-occupied by 
Figure 1. TAL1 regulates a select number of miRNAs in T-ALL cells. (A) TAL1 was silenced by lentiviral knockdown in Jurkat cells and protein ex-
pression was assessed by Western blot. Two independent shRNAs were compared with control shRNAs targeting GFP or luciferase (LUC). (B) Global miRNA 
expression profiling with the Exiqon miRCURY LNA platform after shRNA knockdown of TAL1 in Jurkat cells. Horizontal bars show the mean change in 
log2 median ratios (Hy3/Hy5) ± SD after TAL1 knockdown in duplicate experiments with shRNAs 1 and 2 compared with control shRNAs targeting GFP or 
luciferase. Only miRNAs with a P value ≤ 0.05 by two-tailed Student’s t test are shown. Red bars represent miRNAs bound by TAL1 in Jurkat cells as deter-
mined by ChIP-seq analysis. (C) Quantitative RT-PCR analysis of miR-223 expression normalized to RNU5A in Jurkat cells after TAL1 knockdown with 
shRNAs 1 and 2 compared with a LUC control shRNA. Bars represent mean ± SEM from three independent experiments performed in triplicate. TAL1 was 
silenced in RPMI-8402 (D) and CCRF-CEM (E) cells and miR-223 expression was determined by qRT-PCR. (top) TAL1 expression normalized to GAPDH and 
bottom panel shows miR-223 expression normalized to RNU5A. Bars represent the mean ± SEM of two experiments performed in triplicate. (F) miR-223 
expression was assessed by qRT-PCR in a doxycycline-inducible TAL1 knockdown system developed in Jurkat cells (Jurkat S1C1) for 48 h with (+) or with-
out () the addition of doxycycline (Dox). Bars represent the mean ± SEM of two experiments performed in triplicate. Western blot (bottom) shows TAL1 
protein expression after the addition of doxycycline. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 by two-tailed Student’s t test.
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miRNA is selectively up-regulated in the subset of T-ALLs 
transformed by the TAL1 complex. Of the 19 T-ALL cell lines 
interrogated, 10 overexpressed TAL1, of which 4 harbored 
the SIL-TAL1 deletion (Fig. 3 A). Expression of miR-223 
was significantly higher in the TAL1-positive cell lines as 
compared with the TAL1-negative cells (Fig. 3 B; P < 0.0001). 
To assess whether TAL1 regulates miR-223 in primary T-ALL, 
we also analyzed RNA from primary pediatric T-ALL sam-
ples collected at presentation (Ferrando et al., 2002). Consis-
tent with our findings in T-ALL cell lines, TAL1-positive patients 
exhibited significantly higher expression of miR-223 than 
TAL1-negative patients (P < 0.001), indicating that TAL1 
regulates the expression level of miR-223 in T-ALL cells as 
they exist in patients and not only in T-ALL cell lines growing 
in tissue culture (Fig. 3 C).
In normal murine thymocytes, Tal1 expression is highest 
in early thymic development and then is rapidly silenced as 
the cells differentiate beyond the DN2 stage (Herblot et al., 
2000). To explore whether miR-223 expression is a physio-
logical or promiscuous target of TAL1, we isolated thymic 
subsets from mice and analyzed them for Tal1 and miR-223 
expression by qRT-PCR. In accord with published studies, 
Tal1 expression was highest in early T cell progenitor and 
DN2 cells and was dramatically down-regulated in more dif-
ferentiated cells (Fig. 3 D). Interestingly, miR-223 expression 
closely mirrored Tal1 expression (Pearson’s correlation r = 
0.89; P < 0.001), suggesting that TAL1 regulates miR-223 physi-
ologically during normal thymocyte development (Fig. 3 E). 
Consistent with this finding, TAL1, RUNX1, and LMO2 bind 
the miR-223 promoter in murine hematopoietic precursor-7 
(HPC7) cells, and Gata3 binds the miR-223 promoter in mu-
rine DN1 and DN2 cells, but not in DP cells that do not express 
Tal1 (not depicted; Wilson et al., 2010; Zhang et al., 2012).
Because TAL1 is expressed during early hematopoietic 
development, we also analyzed TAL1 binding at the miR-223 
locus in highly enriched human HSCs (Cui et al., 2009; 
Novershtern et al., 2011). There was significant enrichment 
of TAL1 binding at the miR-223 locus, together with chro-
matin marks consistent with transcriptional activation (Fig. 3 E). 
Thus, in normal hematopoiesis, TAL1 is likely to regulate 
miR-223 as a canonical target in HSCs and in T lymphoid 
progenitors up to the DN2 stage of development, whereas the 
sustained high expression of miR-223 in TAL1-positive T-ALL 
cells, arrested at the DP stage, is clearly aberrant as compared 
with their normal thymocyte counterparts.
TAL1-positive T-ALL cells require  
sustained miR-223 expression
Considering T-ALL cells transformed by the TAL1 oncoprotein 
are dependent on its maintained expression for optimal growth, 
we assessed the contribution of its target, miR-223, to this 
dependency by stably inhibiting mature miR-223 by lentivi-
ral transduction of a miR-223 shRNA construct (termed 
miRZip-223) in T-ALL cell lines. All three T-ALL cell lines 
tested demonstrated significant reductions in growth com-
pared with controls (Fig. 4, A–C), an effect that was mediated 
of RNA polymerase II (RNAPII), indicative of transcrip-
tional initiation and elongation of this locus (Fig. 2 A).
miR-223 and TAL1 expression are closely correlated  
during normal thymic development and in T-ALL
Based on our evidence that the TAL1 complex directly and 
positively regulates miR-223, we investigated whether this 
Figure 2. TAL1 and its partners HEB, E2A, LMO1/2, GATA3, and 
RUNX1 bind a region 4-kb upstream of the miR-223 transcriptional 
start site. (A) ChIP coupled to massively parallel DNA sequencing (ChIP-seq) 
was performed for TAL1, HEB, E2A, and LMO1 or LMO2, GATA3, and RUNX1 
(Sanda et al., 2012). Gene tracks represent binding at the miR-223 locus in a 
human primagraft sample (Prima 5) and the T-ALL cell lines CCRF-CEM (top) 
and Jurkat (bottom), with the miR-223 locus shown below. Y-axis values 
represent the number of sequence reads. (B) Enrichment of miR-223 regions 
indicated in A in four T-ALL cell samples (Jurkat, CCRF-CEM, Prima 2, and 
Prima 5) was analyzed by ChIP-qPCR. Mean ± SD fold enrichment as nor-
malized to binding at the NANOG promoter (negative control) is shown from 
two independent experiments performed in triplicate.
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Figure 3. TAL1 expression correlates with miR-223 expression in human T-ALL and during normal thymic development. (A) TAL1 protein  
expression as determined by Western blot in T-ALL cell lines. The double band is likely to reflect differing TAL1 isoforms. A representative blot from two 
independent experiments is shown. (B) Comparison of miR-223 expression as determined by qRT-PCR in T-ALL cells positive or negative for TAL1. Red 
bars indicate presence of an activating SIL-TAL1 deletion. Bars represent mean ± SEM from two independent experiments performed in triplicate. miR-223  
expression is given as the percentage of RNU5A control. ***, P < 0.001 by two-tailed Student’s t test. (C) miR-223 expression as determined by qRT-PCR  
in 44 pediatric T-ALL patients according to TAL1 expression (n = 22 TAL1-positive; n = 22 TAL1-negative). Horizontal bars represent mean with SEM. TAL1 
status was determined by qRT-PCR. miR-223 expression is given as the percentage of RNU5A control. ***, P < 0.001 by Mann-Whitney-Wilcoxon test. 
Expression levels of TAL1 (D) and miR-223 (E) as determined by qRT-PCR from thymic subsets sorted from mice (Pearson’s correlation, r = 0.89;  
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reporter containing the FBXW7 3UTR, miR-223 exhibited 
the most potent suppression of luciferase activity, a finding 
consistent with other studies (Lerner et al., 2011; Xu et al., 
2010). To demonstrate that this interaction is functional in 
human T-ALL, we stably overexpressed miR-223 in SUP-T1 
and DND41 T-ALL cells, which lack TAL1 and have low miR-
223 levels, and then analyzed endogenous FBXW7 protein 
expression by immunoprecipitation/immunoblot. As expected, 
FBXW7 expression was markedly down-regulated by miR-223 
overexpression in both cell lines, confirming FBXW7 as a 
target of miR-223 in human T-ALL cells (Fig. 6 B). Addition-
ally, inhibition of miR-223 in TAL1-positive cells with the 
miRZip-223 lentivirus resulted in reexpression of FBXW7, 
indicating its protein levels are repressed by miR-223 in these 
cells (Fig. 6 C).
FBXW7, an E3 ubiquitin ligase, targets a host of onco-
proteins, including MYC, MYB, CYCLIN E, MCL-1, MTOR, 
and NOTCH-1 for proteasomal degradation, and is an im-
portant tumor-suppressor in T-ALL, with loss-of-function 
mutations present in 20% of patients (Maser et al., 2007; 
O’Neil et al., 2007; Thompson et al., 2007; Welcker and 
Clurman, 2008). Furthermore, Fbxw7 knockout mice de-
velop T-ALL (Onoyama et al., 2007). Given the dynamic reg-
ulation of miR-223 by TAL1, we hypothesized that TAL1 
represses FBXW7 by controlling miR-223 expression. In-
deed, knockdown of TAL1 with two independent shRNAs in 
two TAL1-positive cell lines led to a significant increase in 
FBXW7 protein expression (Fig. 6 D). This effect was not 
mediated by direct regulation of FBXW7 transcription by 
TAL1, as we did not detect changes in FBXW7 mRNA levels 
after TAL1 knockdown (Sanda et al., 2012).
We also examined known oncogenic substrates of FBXW7, 
to further strengthen the evidence that FBXW7 is the pri-
mary mediator of cell growth inhibition downstream of TAL1 
and its direct target miR-223. After the addition of doxy-
cycline to Jurkat cells harboring a doxycycline-inducible 
TAL1-specific shRNA, the reduction in TAL1 was associ-
ated with re-expression of FBXW7 and a striking reduction 
in the protein levels of MYC, intracellular NOTCH1 (ICN-1), 
MYB, and CYCLIN E (CCNE1), consistent with reactivation 
of FBXW7 activity (Fig. 7 A). However, we observed only 
marginal reductions in MCL-1 protein and no changes in 
MTOR levels, which may relate to cell type–specific aspects 
of the control of degradation of these FBXW7 substrates 
in T-ALL.
Together, our results suggest a model in which the TAL1 
complex directly regulates the expression of miR-223, lead-
ing to its aberrant expression in transformed DP thymocytes, 
where it represses the ubiquitin ligase FBXW7, a tumor sup-
pressor that can degrade oncoproteins with critical functions 
in the pathogenesis of T-ALL (Fig. 7 B).
through an increase in apoptotic cells as determined by 
Annexin V staining (Fig. 4 E). The most dramatic inhibition 
of cell growth was observed in MOLT-16 cells that express 
the highest levels of miR-223 and are FBXW7 wild-type, 
whereas miR-223 inhibition had no effect on the cell growth 
or survival of Be-13 cells that harbor a biallelic deletion of 
FBXW7 (Fig. 4, D and E), indicating that miRZip-223 does 
not have antiproliferative effects other than those caused by 
FBXW7 reexpression (O’Neil et al., 2007). When we retrovi-
rally overexpressed miR-223 in Jurkat cells, it rescued most of 
the phenotype induced by miRZIP-223, arguing against an 
off-target effect by the construct (Fig. 4 F).
We and others have shown that knockdown of TAL1 
slows the growth of TAL1-positive T-ALL cell lines through 
the induction of apoptosis without affecting the cell cycle 
(Palii et al., 2011; Sanda et al., 2012). We thus tested whether 
the decrease in miR-223 expression observed after TAL1 
knockdown was responsible, at least in part, for growth inhi-
bition and apoptosis. We therefore infected the doxycycline-
inducible TAL1 knockdown Jurkat cells with a retroviral vector 
expressing miR-223, such that miR-223 expression was no 
longer under the control of TAL1 in these cells (termed Jurkat-
223 cells). Remarkably, retroviral expression of miR-223 
partially rescued the growth inhibitory effects induced by 
doxycycline-induced TAL1 knockdown, whereas a control 
miR-223 construct in which four bases of the miR-223 seed 
sequence had been mutated (termed Jurkat-mut223) was un-
able to rescue cell growth (Fig. 5 A). Accordingly, levels of 
Annexin V staining and activation of caspases 3 and 7 were 
significantly lower in Jurkat-223 cells after TAL1 knockdown 
as compared with control cells (Fig. 5, B and C). Importantly, 
the degree of TAL1 knockdown was equivalent between 
Jurkat-223 and Jurkat-mut223 cells (Fig. 5 D). Thus, as a key 
downstream target of TAL1, miR-223 is essential for the sur-
vival and optimal growth of TAL1-positive T-ALL cells.
TAL1 regulates the FBXW7 tumor  
suppressor through miR-223
To identify candidate mRNA targets that could mediate the 
effects of miR-223 on cell survival and growth, we interro-
gated computational databases (TargetScan and microRNA.
org; John et al., 2004; Lewis et al., 2005) and published studies 
(Xu et al., 2010; Lerner et al., 2011; Mavrakis et al., 2011). The 
highest ranked target of miR-223 predicted by TargetScan 
is the FBXW7 tumor suppressor, by virtue of three highly 
conserved and one poorly conserved binding site in its 3UTR 
(Fig. 6 A). Notably, the colorectal carcinoma line HCT-
116Dicer1/ shows marked up-regulation of FBXW7 protein 
expression, consistent with its regulation by miRNAs (Xu 
et al., 2010; Lerner et al., 2011). Furthermore, in a miRNA 
library screen to identify miRNAs that can regulate a luciferase 
P < 0.001). Bars represent the mean ± SEM of two experiments performed in triplicate. (F) Gene tracks showing binding of TAL1 in relation to the miR-223 
locus in highly purified human hematopoietic stem cells. Binding of RNA polymerase II (RNAP2), together with H3K4m3 (marking transcriptional initiation) 
and H3K79m2 (marking transcriptional elongation) are also shown. Data are from Cui et al. (2009) and Novershtern et al. (2011).
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et al., 2010; Palii et al., 2011; Sanda et al., 2012). In the T cell 
lineage, TAL1 has preferential binding to E-boxes with adja-
cent GATA, ETS, and RUNX motifs and regulates genes in-
volved in T cell differentiation (Palii et al., 2011). It also targets 
several downstream oncogenes, including MYB, TRIB2, and 
STAT5A (Sanda et al., 2012). Although several other genes 
have been identified as direct targets of TAL1 and its regula-
tory partners in human T-ALL, such as pre–T cell receptor 
DISCUSSION
The t(1;14)(p34;q11) translocation involving TAL1 in T-ALL 
was first described over 20 yr ago (Finger et al., 1989; Bernard 
et al., 1990; Xia et al., 1992), yet the mechanisms through which 
TAL1 is able to transform thymocytes are only beginning to 
be dissected. Studies from our laboratory and others using 
ChIP-seq analysis have shed light on the regulatory networks 
activated during malignant transformation by TAL1 (Wilson 
Figure 4. Inhibition of miR-223 impairs growth and induces apoptosis in TAL1-positive T-ALL cell lines. Four cell lines were transduced with a 
control miRZip shRNA or an shRNA targeting miR-223 (miRZip-223) and growth kinetics were analyzed. (A) Jurkat cells, harboring a heterozygous FBXW7 
R505C mutation (B) CCRF-CEM, harboring a heterozygous FBXW7 R465C mutation (C) MOLT-16, wild-type for FBXW7 and (D) Be-13, which have biallelic 
deletion of the FBXW7 locus. (E) Annexin V expression was determined by flow cytometry in T-ALL cells 72 h after transduction with control miRZip versus 
miRZip-223. (F) Jurkat cells were transduced with a retrovirus to overexpress miR-223 and the growth kinetics analyzed after transduction with miRZip-
control or miRZip-223 shRNA constructs. All data points represent mean ± SEM for triplicate experiments. P values are for *, P < 0.05; **, P < 0.01; and  
***, P < 0.001 by two tailed t test for each time point.
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 (pT), aldehyde dehydrogenase 1 member A2 (ALDH1A2), 
NK3 homeobox 1 (NKX3-1), and cyclin-dependent kinase 6 
(CDK6), the relative contributions of these targets to leuke-
mogenesis remain unclear (Bernard et al., 1998; Ono et al., 
1998; Herblot et al., 2000; Palomero et al., 2006; Kusy et al., 
2010; Palii et al., 2011; Sanda et al., 2012).
Genome-wide analysis of transcription factor binding 
using ChIP-seq has made it possible to assess the direct tran-
scriptional regulation of miRNAs within the genome as a con-
tributing factor to carcinogenesis. Here, we used this approach to 
address the possibility that TAL1-regulated miRNAs contribute 
to the pathogenesis of T-ALL driven by this oncoprotein. Of 
22 miRNAs that changed expression on TAL1 knockdown, we 
identified five as direct targets of the TAL1 complex, including 
miR-26a, miR-29c, miR-181a*, miR-620, and miR-223. Of 
these, miR-223 was selected for further study because it was 
most highly down-regulated upon TAL1 knockdown in sev-
eral different T-ALL cell lines.
Our results are in accord with the notion that TAL1-me-
diated oncogenesis occurs in an anachronistic manner, i.e., the 
physiological target genes of TAL1 are activated at a stage of 
thymocyte differentiation in which they are normally silent. 
Thus, we found evidence of TAL1-binding at the miR-223 
locus in HSCs, and there was a close correlation between 
TAL1 and miR-223 expression throughout normal thymo-
cyte maturation, suggesting that the regulation of miR-223 
by TAL1 is part of a conserved developmental pathway. These 
findings may explain the high levels of miR-223 that have 
been described in T-ALL cases with features characteristic of an 
immature cell of origin (Chiaretti et al., 2010; Van Vlierberghe 
et al., 2011). Considering that miRNA expression during T cell 
development is tightly regulated (Neilson et al., 2007; Ghisi 
et al., 2011; Kirigin et al., 2012), the expression of miR-223 
in DP thymocytes would be expected to aberrantly down-
regulate the expression of several key proteins, including 
FBXW7, that are not normally regulated by this miRNA at 
such a developmental time point.
miR-223 was one of the first miRNAs shown to be ex-
pressed by hematopoietic cells and until recently was considered 
a myeloid-specific miRNA (Chen et al., 2004). In acute promy-
elocytic leukemia, ATRA induces the expression of CCAAT/
enhancer binding protein- (C/EBPA), which up-regulates 
miR-223 through binding to its promoter (Fazi et al., 2005). 
miR-223 then acts to repress nuclear factor-IA (NFI-A), thereby 
contributing to myeloid differentiation (Fazi et al., 2005). 
Whether the regulation of miR-223 by TAL1 contributes to 
early myeloid lineage commitment would be an interesting area 
for future study because the depletion of TAL1 in HSCs leads to 
a reduction in myeloid cells through an unknown mechanism 
(Brunet de la Grange et al., 2006; Zardo et al., 2012).
Using a combination of miRNA expression profiling of 
primary T-ALL patient samples and an unbiased library screen 
Figure 5. miR-223 can partially rescue TAL1-positive cells from 
apoptosis induced by TAL1 knockdown. (A) Doxycycline-inducible 
TAL1-knockdown Jurkat S1C1 cells were retrovirally transduced to express 
miR-223, such that its expression was no longer under the control of 
TAL1. Growth kinetics were assessed with and without the addition of 
doxycycline, compared with control Jurkat S1C1 cells expressing a mutant 
miR-223 in which four bases of the seed sequence had been mutated 
(mut223). Values represent mean ± SD from two experiments performed 
in triplicate. (B) Percentage of Annexin V–positive cells as assayed by flow 
cytometry at 48 h after the addition of doxycycline. (C) Change in cleaved 
caspase-3 and -7 activity as determined by luminescence in the Caspase-
Glo 3/7 assay. Values represent mean ± SEM fold changes from two inde-
pendent experiments performed in triplicate. *, P < 0.05; **, P < 0.01; and 
***, P < 0.001 by two-tailed Student’s t test. (D) Western blot analysis 
showing equivalent TAL1 knockdown between samples.
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Figure 6. TAL1 represses FBXW7 via miR-223 in TAL1-positive T-ALL. (A) Binding sites for miR-223 and the FBXW7 3UTR are shown for three 
conserved and one poorly conserved site (bottom), as determined by the TargetScan algorithm. Position numbers refer to distance from the FBXW7 stop 
codon. (B) TAL1-negative miR-223 low T-ALL cell lines, SUP-T1 and DND-41, were retrovirally transduced to overexpress miR-223, and FBXW7 protein 
expression determined by immunoprecipitation/immunoblot. Loading controls are 10% of immunoprecipitation input. A representative blot from two 
independent experiments is shown. (C) FBXW7 protein expression was determined after transduction of TAL1-positive CCRF-CEM and Jurkat cells with 
miRZip-223 compared with a miRZip control. A representative blot from two independent experiments is shown. (D) TAL1 was depleted in TAL1-positive 
MOLT-16 and RPMI-8402 cells by lentiviral knockdown with two independent shRNAs, and FBXW7 protein expression was determined by immunoprecipi-
tation/immunoblot. A representative blot from two independent experiments is shown.
of miRNAs that were able to rescue lymphocytes from cyto-
kine withdrawal, Mavrakis et al. (2011) recently identified 
several oncogenic miRNAs in T-ALL. Of the miRNAs that 
scored on their screen, miR-223 was the most abundantly 
expressed in T-ALL patients and accelerated Notch-induced 
leukemia in a mouse model, although the mechanism leading 
to its dysregulation in human T-ALL was not established 
(Mavrakis et al., 2011). It is notable that in this study miR-223 
had a pro-survival role in lymphocytes. Similarly, we found 
that inhibition of miR-223 in T-ALL induced apoptosis, sug-
gesting T-ALL cells are dependent on its sustained expression. 
Moreover, in an inducible TAL1 knockdown system, we found 
that miR-223 undergoes significant down-regulation when 
TAL1 expression is blocked, and that retroviral transduction 
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several groups have shown that miR-223 regulates FBXW7 
expression in a variety of cellular contexts (Lerner et al., 2011; 
Mavrakis et al., 2011; Xu et al., 2010). Here, we show miR-223 
can also regulate FBXW7 protein expression in human T-ALL 
cells. The reactivation of FBXW7 protein expression observed 
after TAL1 knockdown indicates it is actively suppressed by 
TAL1 through its regulation of miR-223, although we can-
not rule out the presence of other miR-223 targets important 
to the malignant phenotype. Regulation of FBXW7 positions 
TAL1 at the top of a genetic network that directly stabilizes 
oncoproteins such as c-MYC, MYB, and NOTCH that have 
vital roles in T-ALL pathogenesis. FBXW7 is known to play a 
prominent role as a tumor suppressor in T-ALL, and our paper 
firmly establishes a major mechanism leading to its down-
regulation by TAL1 in the majority of T-ALL cases that lack 
gene-specific FBXW7 inactivating mutations or deletions. 
Our paper implicates a carcinogenic pathway involving over-
expression of an oncogenic transcription factor in the coordi-
nate down-regulation of a key tumor suppressor through a 
miRNA intermediate, and further study will establish whether 
this mechanism is more broadly used in cancer biology.
MATERIALS AND METHODS
T-ALL cell samples. Human T-ALL cell lines were maintained as described 
previously, and the identity of all cell lines was confirmed by short-tandem 
repeat analysis (Sanda et al., 2010). Diagnostic T-ALL samples from TAL1-
positive cases were obtained with informed consent and Institutional Review 
Board approval from children treated on Dana Farber Cancer Institute study 
05–01. The development of primagraft samples for ChIP-seq analysis has 
been previously described (Sanda et al., 2012). RNA was obtained at pre-
sentation from 44 pediatric T-ALL patients as previously reported (Ferrando 
et al., 2002).
Microarray expression analysis for mRNA or miRNA. For global 
miRNA expression analysis, Jurkat cells were harvested at 48 h after lentiviral 
transduction with TAL1 shRNAs 1 and 2, or control shRNAs targeting GFP 
and luciferase, with each shRNA performed in duplicate. Efficient TAL1 
knockdown was assessed by Western blotting. miRNAs were isolated and 
purified with the High Pure miRNA isolation kit (Roche). Global miRNA 
expression profiling was performed with the Exiqon miRCURY LNA fifth 
generation platform (miRBase version 14.0). The difference in log2 median 
ratios (Hy3/Hy5) between sample groups was calculated and significance 
was determined by two-tailed Student’s t test. P values of ≤0.05 were consid-
ered to indicate statistical significance. For mRNA expression analysis, total 
RNA samples were extracted by TRIzol (Invitrogen) from T-ALL cell lines 
grown in parallel under identical conditions and purified by RNeasy Mini 
kit (QIAGEN). Gene expression was analyzed by Affymetrix HG U133 2.0 
plus microarrays.
ChIP. ChIP was performed according to previously described methods 
(Lee et al., 2006). The antibodies and detailed ChIP conditions and analysis 
parameters have been described in detail (Sanda et al., 2012). Data showing 
TAL1 binding and histone modifications in human HSCs were from previous 
studies (Cui et al., 2009; Novershtern et al., 2011). Relative enrichment 
of the miR-223 promoter was determined by ChIP quantitative PCR 
as described Sanda et al. (2012) using the primers miR-223-F1 5-CAGAAA-
GCCCAATTCCATCT-3 and miR-223-R1 5-GGGCAAATGGATAC-
CATACC-3 normalized to the negative control region near the NANOG 
promoter using primers NANOGpr-F1 5-TCACAAGGGTGGGTCAG-
TAG-3 and NANOGpr-R1 5-CCAGCAGAACGTTAAAATCC-3.
of miR-223 significantly rescued cell growth on TAL1 knock-
down. Together these results identify miR-223 as a vital TAL1 
target gene whose expression is essential for the optimal growth 
of TAL1-positive leukemic cells.
By virtue of possessing three conserved binding sites in 
its 3UTR, the FBXW7 tumor suppressor gained the highest 
rank among the miR-223 targets predicted by TargetScan, and 
Figure 7. TAL1 stabilizes a host of oncogenic substrates through 
the repression of FBXW7. Western blots for TAL1, FBXW7, and its sub-
strates MYC, MYB, intracellular NOTCH1 (ICN-1), MTOR, MCL-1 (L, long 
isoform; S, short isoform), and CYCLIN E 48 h after the addition of doxy-
cycline in doxycycline-inducible TAL1-knockdown Jurkat S1C1 cells. Rep-
resentative blots from three independent experiments are shown.
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at 6.25 µg/ml. The level of knockdown was verified by qRT-PCR for RNA 
or by Western blotting.
RNA extraction, cDNA, and expression analysis. miRNAs were iso-
lated and purified with the High Pure miRNA isolation kit (Roche) and 
reverse transcribed with the miScript kit (QIAGEN), and their expression 
was quantitated with the miScript SyberGreen kit using a miScript universal 
primer and miR-223–specific primer (MS00003871; QIAGEN). Expression 
was normalized to expression of RNU5A (MS00013993; QIAGEN). Both 
the miR-223 and RNU5A primers are compatible with human and mouse 
gene orthologues. To assess mRNA knockdown, a small fraction of cells 
were collected and mRNA was extracted by TRIzol (Invitrogen), followed 
by column purification using the RNeasy Mini kit (QIAGEN). Purified 
RNA was reverse-transcribed with the miScript kit (QIAGEN). Quanti-
tative real-time PCR was performed with the AB7300 Detection System 
(Applied Biosystems) using gene-specific primers and Power SYBR Green 
PCR Master Mix (Applied Biosystems). Primer sequences for qRT-PCR 
were as follows: human TAL1-F, 5-AGGGCCTGGTTGAAGAAGAT-3; 
human TAL1-R, 5-AAGTAAGGGCGACTGGGTTT-3; murine Tal1-F, 
5-CCCCATGTTCACCAACAAC-3; murine Tal1-R, 5-CCGCACTAC-
TTTGGTGTGAG-3; GAPDH-F, 5-TGCACCACCAACTGCTTAGC-3; 
GAPDH-R, 5GGCATGGACTGTGGTCATGAG-3. Among T-ALL cases, 
TAL1 expression exhibited a bimodal distribution, and patients were deter-
mined as TAL1-positive if TAL1 transcripts were >3.7% of GAPDH.
Apoptosis assays. Annexin V staining was assessed by flow cytometry using 
Annexin V-APC antibody (BD) according to the manufacturer’s recommen-
dations. Cleaved caspase-3 and -7 activity was determined by luminescence 
using the Caspase-Glo 3/7 assay from Promega after normalization for 
cell number.
Accession nos. Expression data and ChIP-seq can be found in the Gene 
Expression Omnibus under superseries accession no. GSE29181, and chro-
matin marks and RNA Pol II ChIP-seq data from Jurkat are found under 
accession no. GSE33850. Chromatin marks and RNA Pol II in human he-
matopoietic stem and progenitor cells are found under accession no. GSE26015. 
miRNA expression data are available under accession no. GSE46957.
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